No change in SERT availability |
Buchert et al. 2006 |
Humans |
PET, [11C](+)McN5652 |
MDMA abusers – longitudinal design |
Thomasius et al. 2006 |
Humans |
PET, [11C](+)McN5652 |
MDMA abusers – longitudinal design |
Banks et al. 2008 |
Rhesus macaques |
PET, [11C]DASB |
0.03 and 0.3 mg/kg/infusion (IV) MDMA |
Decreases in SERT availability |
Scheffel et al. 1998 |
Baboons |
PET, [11C](+)McN5652 |
5 mg/kg bidaily X 4 days (SC) MDMA |
Ricaurte et al. 2000 |
Humans |
PET, [11C](+)McN5652 |
MDMA abusers |
Increases in SERT availability |
Banks et al. 2008 |
Rhesus macaques |
PET, [11C]DASB |
0.03 and 0.3 mg/kg/infusion (IV) cocaine |
No change in DAT availability |
Czoty et al. 2007 |
Rhesus macaques |
PET, [18F]FCT |
0.03 mg/kg/infusion (IV) cocaine - limited drug intake |
Decreases in DAT availability |
McCann et al. 1998 |
Humans |
PET, [11C]WIN 35,428 |
methamphetamine abusers |
Villemagne et al. 1998 |
Baboons |
PET, [11C]WIN 35,428 |
0.5, 1, or 2 mg/kg X 4 injections (IM) methamphetamine |
Sekine et al. 2001, 2003
|
Humans |
PET, [11C]WIN 35,428 |
methamphetamine abusers |
Reneman et al. 2002 |
Humans |
SPECT, [123I]B-CIT |
amphetamine/MDMA abusers |
Hashimoto et al. 2007 |
Rhesus macaques |
PET, [11C]CFT |
2 mg/kg X 3 injections (IM) methamphetamine |
Volkow et al. 2001a |
Humans |
PET, [11C]d-threo-methylphenidate |
methamphetamine abusers |
No change in vMAT levels |
Fantegrossi et al. 2004 |
Rhesus macaques |
PET, [11C]DTBZ |
0.003 to 0.3 mg/kg/infusion (IV) MDMA |
Decreases in D2 receptor availability |
Volkow et al. 1993 |
Humans |
PET, [11C]raclopride |
cocaine abusers |
Volkow et al. 2001b |
Humans |
PET, [11C]raclopride |
methamphetamine abusers |
Nader et al. 2006 |
Rhesus macaques |
PET, [18F]FCP |
0.2 mg/kg/infusion (IV) cocaine |